Key result
Extracellular vesicles show broad potential as biomarkers, therapeutics, and drug delivery platforms in CVD.
Answers are grounded in this paper and cite their sources.
Cardiovascular diseases (CVD) represent the leading cause of morbidity and mortality globally. The emerging role of extracellular vesicles (EVs) in intercellular communication has stimulated renewed interest in exploring the potential application of EVs as tools for diagnosis, prognosis, and therapy in CVD. The ubiquitous nature of EVs in biological fluids presents a technological advantage compared to current diagnostic tools by virtue of their notable stability. EV contents, such as proteins and microRNAs, represent specific signatures of cellular activation or injury. This feature positions EVs as an alternative source of biomarkers. Furthermore, their intrinsic activity and immunomodulatory properties offer EVs unique opportunities to act as therapeutic agents per se or to serve as drug delivery carriers by acting as miniaturized vehicles incorporating bioactive molecules. In this article, we aim to review the recent advances and applications of EV-based biomarkers and therapeutics. In addition, the potential of EVs as a drug delivery and theranostic platform for CVD will also be discussed.
No takes yet. Share an insight, caveat, or question.
Chong et al. (2019) conducted a review in Cardiovascular diseases. Extracellular vesicles was evaluated. Extracellular vesicles represent a promising platform as alternative sources of biomarkers, direct therapeutic agents, and drug delivery carriers for cardiovascular diseases.
Synapse has enriched 10 related papers. Consider them for comparative context: